EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS
暂无分享,去创建一个
David C Evans | T. Baillie | M. Braun | Y. S. Tang | Wei Tang | G. Doss | D. C. Evans | George A Doss | Thomas A Baillie | Matthew P Braun | Qing Chen | Wensheng Liu | E. Tung | Wei Tang | Ralph A Stearns | Qing Chen | John R Strauss | Yui S Tang | Regina W Wang | R. Stearns | J. Strauss | Elaine C Tung | Wensheng Liu | Varsha Didolkar | Regina W. Wang | V. Didolkar
[1] R Scott Obach,et al. Biotransformation reactions of five-membered aromatic heterocyclic rings. , 2002, Chemical research in toxicology.
[2] R. Jacobs,et al. Anaphylactoid reactions to tolmetin and zomepirac. , 1983, Annals of allergy.
[3] M. Gorrell,et al. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. , 2001, Life sciences.
[4] J. Lasker,et al. Isolation of P450 enzymes from human liver. , 1991, Methods in enzymology.
[5] T. Baillie,et al. Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[6] G. Aithal. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity , 2004, Expert opinion on drug safety.
[7] W. Wu,et al. The metabolism of zomepirac sodium. II. Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man. , 1980, Drug metabolism and disposition: the biological fate of chemicals.
[8] T. Baillie,et al. Mass spectrometry in the analysis of glutathione conjugates. , 1993, Biological mass spectrometry.
[9] L. Benet,et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs , 1995, Nature Medicine.
[10] A. Munafo,et al. Disposition and irreversible plasma protein binding of tolmetin in humans , 1988, Clinical pharmacology and therapeutics.
[11] V. Armstrong,et al. Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications , 2003, Therapeutic drug monitoring.
[12] J. M. Grindel,et al. Review of the Pharmacokinetics and Metabolism of Zomepirac in Man and Animals , 1980, Journal of clinical pharmacology.
[13] L. Benet,et al. Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. , 1990, The Journal of pharmacology and experimental therapeutics.
[14] L. Benet,et al. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. , 1986, The Journal of clinical investigation.
[15] T. Baillie,et al. Bioactivation of diclofenac via benzoquinone imine intermediates-identification of urinary mercapturic acid derivatives in rats and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[16] A. D. Rodrigues,et al. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. , 1999, The Journal of pharmacology and experimental therapeutics.
[17] H. Novey,et al. Anaphylactoid reactions to tolmetin after interrupted dosage. , 1985, The Western journal of medicine.
[18] E M Faed,et al. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. , 1984, Drug metabolism reviews.
[19] Wei Tang,et al. In Vitro Drug Metabolism , 2004 .
[20] U. Boelsterli,et al. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. , 1993, Toxicology and applied pharmacology.
[21] M. Bailey,et al. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. , 1998, Chemico-biological interactions.
[22] P H Li,et al. Actions of corticotropin-releasing factor or cortisol on follicle-stimulating hormone secretion by isolated pig pituitary cells. , 1993, Life sciences.
[23] R. Boulieu,et al. Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[24] E. Vasilomanolakis,et al. Anaphylactic Reaction Due to Zomepirac , 1984, Drug intelligence & clinical pharmacy.
[25] Zhengyin Yan,et al. DETECTION OF A NOVEL REACTIVE METABOLITE OF DICLOFENAC: EVIDENCE FOR CYP2C9-MEDIATED BIOACTIVATION VIA ARENE OXIDES , 2005, Drug Metabolism and Disposition.
[26] L. Benet,et al. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? , 1992, Drug metabolism reviews.
[27] D. Marguet,et al. Hepatic covalent adduct formation with zomepirac in the CD26‐deficient mouse , 2002, Journal of gastroenterology and hepatology.
[28] S. Cucinell,et al. Metabolism of tolmetin in rat, monkey, and man. , 1975, Drug metabolism and disposition: the biological fate of chemicals.
[29] Wei Tang. The metabolism of diclofenac--enzymology and toxicology perspectives. , 2003, Current drug metabolism.
[30] Yue Chen,et al. IDENTIFICATION OF A NOVEL GLUTATHIONE ADDUCT OF DICLOFENAC, 4′-HYDROXY-2′-GLUTATHION-DESCHLORO-DICLOFENAC, UPON INCUBATION WITH HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.
[31] L. Benet,et al. Predictability of the covalent binding of acidic drugs in man. , 1993, Life sciences.